Answers are grounded in this paper and cite their sources.
Historically, patients with skin of color are underdiagnosed with psoriasis and underrepresented in clinical trials. In this study, we assess the efficacy and safety of risankizumab in patients with moderate-to-severe plaque psoriasis by race and ethnicity in the open label extension LIMMitless (NCT03047395).
No takes yet. Share an insight, caveat, or question.
Alexis et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: